Vilya
Vilya is a computational biotechnology company focused on creating a new class of medicines by precisely targeting disease biology. Their platform leverages advanced computational approaches and explores uncharted chemical space to design novel molecular structures, including macrocycles, that possess enhanced drug-like properties. Vilya aims to revolutionize medicine creation by using computing to surpass traditional high-throughput screening methods and ultimately cure diseases. The company was co-founded by scientists from the Institute of Protein Design (IPD), led by David Baker, Ph.D., and ARCH Venture Partners. Recent news highlights include Dr. David Baker's Nobel Prize in Chemistry and a $71 million Series A financing expansion to advance their computational drug design.
Vilya
Vilya is a computational biotechnology company focused on creating a new class of medicines by precisely targeting disease biology. Their platform leverages advanced computational approaches and explores uncharted chemical space to design novel molecular structures, including macrocycles, that possess enhanced drug-like properties. Vilya aims to revolutionize medicine creation by using computing to surpass traditional high-throughput screening methods and ultimately cure diseases. The company was co-founded by scientists from the Institute of Protein Design (IPD), led by David Baker, Ph.D., and ARCH Venture Partners. Recent news highlights include Dr. David Baker's Nobel Prize in Chemistry and a $71 million Series A financing expansion to advance their computational drug design.